- Investing Ideas
- /
- Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
16
0 new
Companies with a Value score of at least 3, ordered by Value score
16 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
MRK | AR$22,175.00 | -2.7% | 16.1% | AR$246.5b | AR$29,830.74 | PE20.3x | E15.6% | 3.2% | ||
GILD | AR$24,975.00 | -5.8% | 39.1% | AR$110.5b | AR$27,311.84 | PE876.6x | E40.9% | 3.5% | ||
BIIB | AR$13,500.00 | -8.3% | -23.9% | AR$22.7b | AR$21,781.46 | PE14.1x | E12.4% | n/a | ||
BMY | AR$21,600.00 | -3.4% | 28.7% | AR$117.4b | AR$22,155.71 | PS2.5x | E48.6% | 4.1% | ||
MRKD | US$21.25 | 1.2% | -0.7% | US$246.5b | US$28.59 | PE20.3x | E15.6% | 3.2% | ||
BIIBD | US$12.70 | -3.1% | n/a | US$22.7b | US$20.49 | PE14.1x | E12.4% | n/a | ||
GSKD | US$8.75 | -18.2% | 6.7% | US$53.0b | US$12.49 | PE21.1x | E21.9% | 4.5% | ||
NVSD | US$28.40 | 0% | n/a | US$181.9b | US$32.25 | PE17.5x | E7.0% | 3.5% | ||
NVS | AR$28,750.00 | -3.7% | 29.6% | AR$183.1b | AR$32,345.17 | PE17.6x | E7.0% | 3.5% | ||
ROSE | AR$115.75 | 13.8% | 106.3% | AR$4.4b | n/a | PE4.9x | n/a | n/a | ||
GSK | AR$9,360.00 | -7.6% | 14.1% | AR$53.4b | AR$13,262.60 | PE21.3x | E21.9% | 4.4% | ||
GILDD | US$22.70 | -1.3% | 3.2% | US$110.5b | US$24.82 | PE876.6x | E40.9% | 3.5% | ||
AMGND | US$10.00 | 0% | 30.4% | US$150.5b | US$11.60 | PE36.6x | E19.1% | 3.1% | ||
TMOD | US$28.50 | 0% | n/a | US$196.2b | US$36.34 | PE32x | E11.5% | 0.3% | ||
AMGN | AR$10,775.00 | -5.5% | 30.3% | AR$154.7b | AR$12,503.88 | PE36.6x | E19.1% | 3.1% | ||
TMO | AR$26,000.00 | -6.9% | 25.1% | AR$196.2b | AR$33,153.50 | PE32x | E11.5% | 0.3% |
Page 1 of 1